Literature DB >> 21524811

RETRACTED: Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes.

Jun Iwamoto1, Yoshihiro Sato2, Mitsuyoshi Uzawa3, Tsuyoshi Takeda4, Hideo Matsumoto4.   

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief due to concerns about the integrity of the research reported. The concerns include but are not limited to study conduct, including discrepancies in reporting of study design and methodology, unacknowledged text and data duplication, and implausible timeframes and data.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21524811     DOI： 10.1016/j.diabres.2011.03.033

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  7 in total

1.  Glucocorticoid use and its association with skeletal health among U.S. adults with diabetes.

Authors:  Sarah Stark Casagrande; Catherine C Cowie; Saul Malozowski
Journal:  J Diabetes Complications       Date:  2016-06-27       Impact factor: 2.852

2.  The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.

Authors:  Emily Jane Gallagher; Hui Sun; Caroline Kornhauser; Aviva Tobin-Hess; Sol Epstein; Shoshana Yakar; Derek LeRoith
Journal:  Diabetes Metab Res Rev       Date:  2014-03       Impact factor: 4.876

3.  [Diabetes and osteoporosis: pathophysiological interactions and clinical importance for geriatric patients].

Authors:  M Lechleitner; K Pils; R Roller-Wirnsberger; E Beubler; R Gasser; P Mrak; F Hoppichler; P Pietschmann
Journal:  Z Gerontol Geriatr       Date:  2013-07       Impact factor: 1.281

Review 4.  Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review.

Authors:  Panagiotis Anagnostis; Stavroula A Paschou; Nifon N Gkekas; Aikaterini-Maria Artzouchaltzi; Konstantinos Christou; Dimitrios Stogiannou; Andromachi Vryonidou; Michael Potoupnis; Dimitrios G Goulis
Journal:  Endocrine       Date:  2018-02-06       Impact factor: 3.633

5.  Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Tsuyoshi Takeda; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2011-06-29       Impact factor: 2.423

Review 6.  Diagnosis and management of bone fragility in diabetes: an emerging challenge.

Authors:  S L Ferrari; B Abrahamsen; N Napoli; K Akesson; M Chandran; R Eastell; G El-Hajj Fuleihan; R Josse; D L Kendler; M Kraenzlin; A Suzuki; D D Pierroz; A V Schwartz; W D Leslie
Journal:  Osteoporos Int       Date:  2018-07-31       Impact factor: 4.507

Review 7.  Skeletal Fragility in Type 2 Diabetes Mellitus.

Authors:  Jakob Starup-Linde; Katrine Hygum; Bente Lomholt Langdahl
Journal:  Endocrinol Metab (Seoul)       Date:  2018-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.